Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
Clinical trial NCT05625087 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05625087
- Sponsor
- UNICANCER
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-19
- Primary completion
- 2028-07-01
- Enrollment
- 162
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.